Lin Shih-Hsien, Tseng Huai-Hsuan, Tsai Hsin Chun, Chi Mei Hung, Lee I Hui, Chen Po See, Chen Kao Chin, Yang Yen Kuang
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):155-159. doi: 10.9758/cpn.2021.19.1.155.
Weight gain is an important risk factor for morbidity and mortality among patients with schizophrenia. We speculated that positive symptoms, related to dopaminergic hyperactivity and altered mesolimbic function, are associated with weight gain.
Twenty-two antipsychotic-naïve, first-episode patients with schizophrenia were enrolled. The Positive and Negative Syndrome Scale was completed at enrollment and follow-up. Body mass index (BMI) was also measured.
The increase in BMI, after 6.04 ± 2.16 years of follow-up, was associated with positive symptoms, but not negative symptoms, before treatment with antipsychotics in antipsychotic-naïve patients with schizophrenia.
This finding implied that dopaminergic hyperactivity could be an important factor to predict the treatment outcome. Body weight control is important for the health management of patients with schizophrenia with more severe positive symptoms.
体重增加是精神分裂症患者发病和死亡的重要危险因素。我们推测，与多巴胺能亢进及中脑边缘系统功能改变相关的阳性症状与体重增加有关。
纳入22例未使用过抗精神病药物的首发精神分裂症患者。在入组时和随访时完成阳性和阴性症状量表评估。同时测量体重指数（BMI）。
在未使用过抗精神病药物的精神分裂症患者中，经过6.04±2.16年的随访，BMI的增加与抗精神病药物治疗前的阳性症状相关，而与阴性症状无关。
这一发现表明多巴胺能亢进可能是预测治疗结果的一个重要因素。对于具有更严重阳性症状的精神分裂症患者，控制体重对其健康管理很重要。
